AbbVie (ABBV) EBT Margin (2012 - 2026)
AbbVie's (ABBV) quarterly EBT Margin came in at 25.18% in Q2 2026, up 1510.0% year-over-year from 1.56% in Q2 2025, and up 263.56% quarter-over-quarter from 6.93% in Q1 2026.
Powered by 
Analysis
AbbVie (ABBV) EBT Margin (2012 - 2026) Analysis & Trends
AbbVie (ABBV) has reported EBT Margin for 15 consecutive years, with 25.18% the latest figure, recorded in Q2 2026.
- On a quarterly basis, EBT Margin rose 1510.0% year-over-year to 25.18% in Q2 2026; TTM through Jun 2026 was 13.51%, a 832.0% increase from a year earlier, with the FY2025 full-year figure at 10.79%, up 419.0% from the prior year.
- EBT Margin was 25.18% for Q2 2026 at AbbVie, up from 6.93% in the prior quarter.
- Over five years, EBT Margin peaked at 36.41% in Q1 2022 and troughed at 15.02% in Q4 2024.
- A 5-year average of 13.49% and a median of 14.14% in 2024 frame the typical range for EBT Margin.
- Across the five-year window, EBT Margin slumped 3252 bps in 2023 and surged 3108 bps in 2025, its largest moves.
- Over 5 years, EBT Margin stood at 19.61% in 2022, then tumbled by 57 bps to 8.47% in 2023, then sank by 277 bps to 15.02% in 2024, then jumped by 207 bps to 16.05% in 2025, then soared by 57 bps to 25.18% in 2026.
- The last three EBT Margin figures came in at 25.18% (Q2 2026), 6.93% (Q1 2026), and 16.05% (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 641.14 Bn | 620.38 Bn | 17.26 Bn | 26.66% |
| 2 | AbbVie | 451.04 Bn | 444.47 Bn | 12.70 Bn | 25.18% |
| 3 | Merck | 357.43 Bn | 350.29 Bn | 12.21 Bn | -4.11% |
| 4 | Novartis Ag | 266.73 Bn | 259.04 Bn | 11.24 Bn | 29.63% |
| 5 | Pfizer | 157.52 Bn | 145.82 Bn | 10.94 Bn | -4.34% |
| 6 | Sanofi | 52.14 Bn | 44.76 Bn | 10.79 Bn | 12.17% |
| 7 | Revolution Medicines | 42.88 Bn | 42.88 Bn | - | - |
| 8 | Incyte | 24.70 Bn | 20.16 Bn | 1.57 Bn | 44.89% |
| 9 | United Therapeutics | 21.47 Bn | 18.80 Bn | 683.80 Mn | 47.58% |
| 10 | Neurocrine Biosciences | 15.82 Bn | 15.43 Bn | 935.80 Mn | 16.91% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 25.18% |
| Mar 31, 2026 | 6.93% |
| Dec 31, 2025 | 16.05% |
| Sep 30, 2025 | 4.53% |
| Jun 30, 2025 | 10.08% |
| Mar 31, 2025 | 12.45% |
| Dec 31, 2024 | -15.02% |
| Sep 30, 2024 | 14.41% |
| Jun 30, 2024 | 14.84% |
| Mar 31, 2024 | 14.26% |
| Dec 31, 2023 | 8.47% |
| Sep 30, 2023 | 14.02% |
| Jun 30, 2023 | 18.82% |
| Mar 31, 2023 | 3.89% |
| Dec 31, 2022 | 19.61% |
| Sep 30, 2022 | 29.71% |
| Jun 30, 2022 | 8.11% |
| Mar 31, 2022 | 36.41% |
| Dec 31, 2021 | 28.69% |
| Sep 30, 2021 | 25.71% |